全文获取类型
收费全文 | 409篇 |
免费 | 20篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 18篇 |
妇产科学 | 7篇 |
基础医学 | 50篇 |
口腔科学 | 6篇 |
临床医学 | 27篇 |
内科学 | 129篇 |
皮肤病学 | 8篇 |
神经病学 | 13篇 |
特种医学 | 39篇 |
外科学 | 77篇 |
综合类 | 3篇 |
预防医学 | 22篇 |
眼科学 | 3篇 |
药学 | 11篇 |
肿瘤学 | 22篇 |
出版年
2022年 | 4篇 |
2021年 | 8篇 |
2020年 | 4篇 |
2019年 | 5篇 |
2018年 | 8篇 |
2017年 | 9篇 |
2016年 | 6篇 |
2015年 | 6篇 |
2014年 | 10篇 |
2013年 | 12篇 |
2012年 | 12篇 |
2011年 | 18篇 |
2010年 | 18篇 |
2009年 | 16篇 |
2008年 | 14篇 |
2007年 | 14篇 |
2006年 | 12篇 |
2005年 | 28篇 |
2004年 | 8篇 |
2003年 | 15篇 |
2002年 | 5篇 |
2001年 | 7篇 |
2000年 | 2篇 |
1999年 | 11篇 |
1998年 | 12篇 |
1997年 | 12篇 |
1996年 | 19篇 |
1995年 | 13篇 |
1994年 | 14篇 |
1993年 | 17篇 |
1992年 | 6篇 |
1991年 | 2篇 |
1990年 | 5篇 |
1989年 | 8篇 |
1988年 | 9篇 |
1987年 | 9篇 |
1986年 | 7篇 |
1985年 | 9篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1981年 | 4篇 |
1980年 | 6篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1959年 | 2篇 |
1919年 | 1篇 |
1889年 | 1篇 |
排序方式: 共有436条查询结果,搜索用时 15 毫秒
11.
McLean Andrew Mukherjee Ankur Phukan Chandan Veeratterapillay Rajan Soomro Naeem Somani Bhaskar Rai Bhavan Prasad 《Journal of robotic surgery》2020,14(1):1-9
Journal of Robotic Surgery - To systematically review world literature and compare peri-operative outcome including operating time (OT), estimated blood loss (EBL), warm ischemia time (WIT), length... 相似文献
12.
13.
Weaver CH; Buckner CD; Longin K; Appelbaum FR; Rowley S; Lilleby K; Miser J; Storb R; Hansen JA; Bensinger W 《Blood》1993,82(7):1981-1984
Five syngeneic transplants were performed in four patients following myeloablative therapy using unmodified peripheral blood mononuclear cells (PBMCs) collected after the administration of recombinant human granulocyte colony stimulating factor (rhG-CSF) to normal donors. The only toxicity experienced by the four normal donors was bone pain. Four patients received two collections of PBMCs, and a second transplant was performed in one patient with one collection. The patients received a median of 20.53 x 10(8) total nucleated cells/kg (range 20 to 25.5), 11.3 x 10(8) total mononuclear cells/kg (range 6.52 to 17.2), 113.1 x 10(4)/kg CFU-GM (range 46.7 to 211.8) and 9.6 x 10(6) CD34+ cells/kg (range 1.6 to 12.6) Post-transplant growth factors were not administered. The median time to an absolute neutrophil count greater than 0.5 x 10(9)/L was 14 days (range 10 to 18). The median time to platelet transfusion independence was 11 days (range 10 to 13). Two patients had the number of CD3+ T lymphocytes determined in the pheresis product. An average of 3.04 x 10(10) CD3+ cells were collected per pheresis. This represents an approximate 1 log increase over the number of T lymphocytes in a typical bone marrow transplant. Rh-GCSF can be used to mobilize peripheral blood progenitor cells from normal donors with minimal toxicity. Studies of allogeneic transplants using PBMCs collected after rhG-CSF administration to determine permanent grafting ability and the incidence and severity of graft-versus-host disease are warranted. 相似文献
14.
Storb R; Raff RF; Appelbaum FR; Deeg HJ; Graham TC; Schuening FG; Shulman H; Yu C; Bryant E; Burnett R 《Blood》1994,84(10):3558-3566
Previous studies found that bone marrow (BM) allografts from DLA- identical littermates resulted in survival of two thirds of recipient dogs after otherwise lethal doses of 450 to 600 cGy of total body irradiation (TBI) because of successful allografts or autologous recovery after rejection of the allografts. The current study asked whether survival could be further improved by treating allograft recipients with recombinant canine granulocyte colony-stimulating factor (G-CSF), stem cell factor (SCF), or G-CSF/SCF. Of 21 dogs, 14 (67%) receiving allografts but no growth factors survived, 10 with successful allografts (including 5 mixed chimeras) and 4 with autologous recovery; whereas 7 animals died, 5 from infections during BM aplasia and 2 from acute graft-versus-host disease. By comparison, 30 of 34 dogs (88%) receiving hematopoietic growth factors in addition to the BM graft survived, 17 with successful allografts (including 10 mixed chimeras) and 13 with autologous recovery; whereas 4 died, all with infection related to BM aplasia after rejection of the allograft. Survival was similar for recipients of G-CSF, SCF, or the combination of G-CSF and SCF. Logistic regression analyses, which accounted for possible effects of TBI dose, showed a trend for improved survival in dogs receiving growth factors (P = .09), no change in allogeneic engraftment (P = .74), and a slight increase in autologous recovery (P = .22). In agreement with previous data, we found that grafts of BM from DLA-identical littermates improved survival of recipient dogs exposed to low but otherwise lethal doses of TBI. A further improvement in survival could be achieved by additional treatment with G-CSF, SCF, or G-CSF/SCF. Results suggest that treatment by hematopoietic growth factors along with BM grafts should be considered for victims of radiation accidents. 相似文献
15.
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811 总被引:23,自引:13,他引:23
Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR 《Blood》1995,85(8):2025-2037
The goal of this phase II multicenter clinical trial was to evaluate a new intensive chemotherapy program for adults with untreated acute lymphoblastic leukemia (ALL) and to examine prospectively the impact of clinical and biologic characteristics on the outcome. One hundred ninety-seven eligible and evaluable patients (16 to 80 years of age; median, 32 years of age) received cyclophosphamide, daunorubicin, vincristine, prednisone, and L-asparaginase; 167 patients (85%) achieved a complete remission (CR), 13 (7%) had refractory disease, and 17 (9%) died during induction. A higher CR rate was observed in younger patients (94% for those < 30 years old, 85% for those 30 to 59 years old, and 39% for those > or = 60 years old, P < .001) and in those who had a mediastinal mass (100%) or blasts with a T-cell immunophenotype. Eighty percent of B-lineage and 97% of T-cell ALL patients achieved a CR (P = .01). The coexpression of myeloid antigens did not affect the response rate or duration. Seventy percent of those with cytogenetic or molecular evidence of the Philadelphia (Ph) chromosome and 84% of those without such evidence achieved a CR (P = .11). Patients in remission received multiagent consolidation treatment, central nervous system prophylaxis, late intensification, and maintenance chemotherapy for a total of 24 months. After a median follow-up time of 43 months, the median survival for all 197 patients is 36 months; the median remission duration for the 167 CR patients is 29 months. Favorable pretreatment characteristics relative to remission duration or survival are younger age, the presence of a mediastinal mass or lymphadenopathy, a white blood cell count (WBC) less than 30,000/microL, L1 morphology, T or TMy immunophenotype, and the absence of the Ph chromosome. The estimates of the proportion surviving at 3 years are 69% for patients less than 30 years old, 39% for those 30 to 59 years old, 89% for those who had a mediastinal mass, 59% with WBC less than 30,000/microL, 63% with L1 morphology, 69% for T or TMy antigen expression, and 62% for those who lack the Ph chromosome. Fifteen patients (8%) had no unfavorable prognostic factors and have an estimated probability of survival at 5 years of 100% (95% confidence interval, 77% to 100%). This intensive chemotherapy regimen produces a high remission rate and a high proportion of durable remissions in adults with ALL. 相似文献
16.
Sadam Hussain Tumrani Razium Ali Soomro Xiao Zhang Danish Ali Bhutto Nabi Bux Xiaodong Ji 《RSC advances》2021,11(42):26110
The overall cost and efficiency of an adsorbent material is a major issue in deriving a sorbent into commercial markets. In this study, efforts have been directed to produce adsorption-capable zeolites from the dispensable product of coal power plants, i.e., coal fly ash (CFA). In addition, coal mining water (CW) was used as a direct hydrothermal solvent. The mine water from China''s coal mines was used in this experiment to substitute tap water (TP) for synthesizing zeolite from C-type fly ashes with different crystallization temperatures (45 to 95 °C). Here, CW led to the formation of X-type and A-type zeolites of comparable size. Regarding the proper utilization of waste products, i.e., coal fly ash and mine water, the study paves a simple yet extremely cost-effective approach to synthesize workable zeolitic materials for adsorption purposes. The detailed characterization justified the use of CW as a better solvent than TP to prepare zeolites based on their better granular size and fewer carbon impurities. The prepared zeolites were later used as an adsorbent for the trace removal of ceftazidime (CAZ), taken as a model pharmaceutical pollutant. The zeolites prepared using CW realised a higher adsorption capacity of 80 mg g−1 during 20 min of agitation time. The pH, concentration, and external salt effects were also studied to achieve maximum removal efficiency. In general, the proposed approach enables the production of affordable yet efficient zeolite-based adsorbent materials without consuming any toxic and expensive reagents for practical application in environmental remediations.Diagram showing a systematic approach to preparing zeolites using the hydrothermal approach with the coal mine water and tap water as dissolution solvents. 相似文献
17.
18.
Peter Phiri Isabel Clarke Lydia Baxter Yu-Tian Zeng Jian-Qing Shi Xin-Yuan Tang Shanaya Rathod Mustafa G Soomro Gayathri Delanerolle Farooq Naeem 《World Journal of Psychiatry》2023,13(1):15-35
BACKGROUND Recommendations for psychotherapy have evolved over the years, with cognitive behavioral therapy(CBT) taking precedence since its inception within clinical guidelines in the United Kingdom and United States. The use of CBT for severe mental illness is now more common globally.AIM To investigate the feasibility and acceptability of a culturally adapted, CBT-based, third-wave therapy manual using the Comprehend, Cope, and Connect approach with individuals from a diverse population prese... 相似文献
19.
20.
ER Brown KA Charles SA Hoare RL Rye DI Jodrell RE Aird R Vora U Prabhakar M Nakada RE Corringham M DeWitte C Sturgeon D Propper FR Balkwill JF Smyth 《Annals of oncology》2008,19(7):1340-1346
BACKGROUND: Tumour necrosis factor-alpha (TNF-alpha) is an important regulator of the chronic inflammation contributing to tumour progression. Infliximab, an anti-TNF-alpha monoclonal antibody was investigated in this trial of patients with advanced cancer. The primary objectives were to determine the safety profile and biological response of infliximab in a cancer population. Clinical response was a secondary objective. PATIENTS AND METHODS: Forty-one patients received infliximab at 5 mg/kg (n = 21) or 10 mg/kg (n = 20) i.v. at 0 and 2 weeks and then every 4 weeks. Post-treatment samples were measured for changes in plasma and serum TNF-alpha, CCL2, IL-6 and C-reactive protein (CRP). RESULTS: Infliximab was well tolerated with no dose-limiting toxic effects. At both doses of infliximab, neutralisation of serum TNF-alpha was observed after 1 h while plasma CCL2, IL-6 and serum CRP were decreased 24 and 48 h following infliximab administration. Seven patients experienced disease stablisation (range 10-50+ weeks). There was no evidence of disease acceleration in any patient. CONCLUSIONS: Infliximab treatment was safe and well tolerated in patients with advanced cancer. There was evidence of biological activity with baseline TNF-alpha and CCL2 being correlated with infliximab response. 相似文献